Monitoring the Effect of Tributyltin Salicylate and Propionate, Retinoid X Receptor Ligands, on Heat Shock Protein Expression in MDA‐MB‐231 Cells by MALDI MS/MS Authors: Dana Strouhalova, Dana Macejova, Julius Brtko, Janette Bobalova Published: 2026 ABSTRACT ABSTRACTOrganotin (IV) compounds are known to induce apoptosis via the intrinsic mitochondrial pathway, which is a key mechanism of effective anticancer therapy. Their ability to selectively promote apoptotic cell death highlights their potential as chemotherapeutic agents. In this study, the in vitro effects of two triorganotin compounds, tributyltin propionate and tributyltin salicylate, on the human breast cancer cell line MDA‐MB‐231 were evaluated. In addition to their proven antitumor activity, these compounds may act as synthetic ligands for nuclear retinoid X receptors. Protein expression profiles were examined using gel electrophoresis and MALDI‐TOF mass spectrometry, with a particular focus on heat shock proteins (HSPs), which are commonly overexpressed in cancer cells and contribute to tumor progression and therapeutic resistance. Both triorganotin derivatives significantly reduced HSP expression, suggesting that HSPs could be a promising target in cancer therapy.Keywords: breast cancer, heat shock proteins family, MALDI MS/MS, proteomic, tributyltin salicylate and tributyltin propionate Introduction Organotin (IV) compounds exhibit a wide range of biological activities, including antitumor, anti‐inflammatory, antifungal, and antimicrobial effects, which result from synergistic ligand binding interactions that enhance biological efficacy [1, 2]. In particular, the ability to selectively induce apoptotic cell death is a characteristic feature of effective anticancer agents and underscores the therapeutic significance of organotin (IV) compounds. Triorganotin compounds target nuclear retinoid X receptors (RXRs), which belong to the nuclear receptor superfamily [3]. They act as potent agonists of RXRs, which function as promiscuous heterodimeric partners for a number of other nuclear receptors, including, for example, retinoid‐activated receptors (RARs), thyroid hormone receptors (TRs), dihydroxyvitamin D3 receptors (VDRs), peroxisome proliferator‐activated receptors (PPAR), liver X receptors (LXR), farnesoid X receptor (FXR), pregnane X receptor (PXR), constitutive androstan receptor (CAR), and several orphan nuclear receptors [4]. Thus, RXR molecules play a central role in the endocrine system due to their unique capacity to form heterodimers with other nuclear receptors. Furthermore, specific RXR subtypes have been identified as key regulators of multiple endocrine processes [5]. 9‐cis‐Retinoic acid (9‐cRA), which is the main natural ligand for RXR, can also act as a ligand for several nuclear receptors and take place in regulating their activity. Synthetic RXR agonists act by activating more permissive or potential ligand partner conditional heterodimeric nuclear receptor complexes. Therefore, RXR receptors are a valuable tool for targeting nuclear receptor pathways and gaining new insights into their mechanism of action [6]. Over the past few decades, a large number of RXR agonists and antagonists have been synthesized and are being thoroughly investigated in many laboratories around the world. Organometallic preparations are gaining importance in human oncology [7, 8]. Several triorganotin compounds, for example, triorganotin chlorides, exhibit cytotoxicity toward human breast cancer cells, which has been proven in the MCF‐7, estrogen receptors positive cell line. Tributyl chloride (TBT‐Cl) was more potent than triphenyl chloride (TPT‐Cl) in inhibiting breast cancer. TBT‐Cl showed higher p53 expression compared to TPT‐Cl. In addition, both TBT‐Cl and TPT‐Cl slightly increased Bax expression. TPT‐Cl resulted in a significant reduction in Bcl‐2 expression compared with TBT‐Cl‐treated cells [9]. Additional findings obtained by Strouhalova et al. clearly showed that triorganotin chlorides influenced the expression of several biologically relevant proteins and the results were highly reproducible. These proteins include vimentin, annexin 5, and nucleoside diphosphate kinase B [10]. The study by Strouhalova et al. [11] focused on combining the anticancer properties of two distinct chemical classes, isothiocyanates and triorganotins, into novel, non‐commercially available compounds: tributyltin isothiocyanate (TBT‐ITC) and triphenyltin isothiocyanate (TPT‐ITC). TBT‐ITC and TPT‐ITC were further employed to examine the effects of triorganotin isothiocyanates on vimentin expression, both in the presence and absence of the natural RAR ligand, all‐trans retinoic acid (ATRA) in human triple‐negative MDA‐MB‐231 breast cancer cells. Both triorganotin compounds tested showed similar reductions in vimentin expression, but TBT‐ITC was found to be more potent than TPT‐ITC. In addition, the impact of 9cRA, a natural RXR ligand, and synthetic RXR ligands, either chloride or isothiocyanate derivatives, on vimentin expression was compared. Hunakova et al. [12] recently compared the genotoxic effects of TBT‐ITC and TPT‐ITC in human breast cancer cell lines MCF‐7 and MDA‐MB‐231, demonstrating that DNA damage induced by these compounds may underlie their cytotoxicity in the studied cells. Triphenyltin isoselenocyanate (TPT‐NCSe), a new triorganotin derivative which contains a selenium atom, represents a novel cognate bioactive ligand for RXR. TPT‐NCSe reduced the viability of human breast cancer MCF‐7 and MDA‐MB‐231 cells in a concentration‐ and time‐dependent manner. The data further indicate that TPT‐NCSe induces apoptosis through a caspase cascade initiated via the mitochondrial pathway. TPT‐NCSe also modulates the expression of apoptosis‐related proteins, including Annexin A5, Bcl‐2, and BAX family members, and upregulates the expression of the associated nuclear receptor subtypes RXRα and RXRβ [13]. Another organotin derivative, tributyltin ferulate (TBT‐F), has been tested in the treatment of colon cancer. When TBT‐F alone was used on HCT116 and Caco‐2 tumor cells, endoplasmic reticulum stress, and cell autophagy, but not apoptosis, were found to occur [14]. Subsequently, a more effective complex was formed by combining tributyltin, ferulic acid, and bortezomib. The desire to create compounds with less damage to healthy cells and better anti‐cancer effects has led research to use other derivatives such as the nuclear RXR‐binding ligands tributyltin salicylate (TBT‐SAL) and tributyltin propionate (TBT‐PROP). Recent data obtained in silico and in vitro showed that both derivatives represent new agonists of the nuclear RXR that were able to induce transcriptional activity via nuclear TRs [15]. In our study, we used proteomic approaches to investigate the effects of TBT‐SAL and TBT‐PROP on the MDA‐MB‐231 breast cancer cell line. Proteomic analysis identified several proteins that differed in their expression between control and treated samples. Among these proteins, attention was focused on the basic molecular chaperones, especially on their important representatives: Hsp70, Hsp72, Hsp90‐alpha, and Hsp90‐beta [16]. Heat shock proteins (Hsps) are highly expressed in a broad spectrum of human tumors and are involved in proliferation, differentiation, invasion and metastasis. Specifically, elevated Hsp27 levels correlate with poor prognosis in gastric, liver, prostate, and osteosarcoma cancers, whereas Hsp70 overexpression is linked to poor prognosis in breast cancer [17]. Their post‐translational modifications (e.g., phosphorylation, GlcNAcylation, N‐glycosylation, and nitration) also contribute to breast cancer incidence and drug resistance. Given its role in promoting breast cancer, Hsp70 represents a potential therapeutic target, and its inhibition may offer clinical benefit for patients. Therefore, it is desirable to inhibit Hsp70, which would lead to a tumor‐specific breast cancer cell death program, but would have no effect on non‐tumor breast epithelial cells or normal human fibroblasts. Several small molecule inhibitors as well as peptide inhibitors of Hsp70 have so far been validated in breast cancer models with promising efficacies. For example, epigallocatechin‐3‐gallate–mediated inhibition of Hsp70 expression reduced cell proliferation and colony formation in MCF‐7 breast cancer cells [16]. Sulforaphane, a natural isothiocyanate inhibitor of Hsp27, Hsp70, and Hsp90 expression, induced apoptosis in MCF‐7 and MDA‐MB‐231 breast carcinoma cells [18]. Combining current breast cancer treatment with drugs that inhibit targeted proteins may reduce tumor burden, metastasis, and drug resistance [19]. For this reason, further experiments and a focus on new derivatives are needed, and therefore, our goal was to test additional RXR agonists, TBT‐SAL, and TBT‐PROP. Materials and Methods Chemicals and Samples Tributyltin salicylate (TBT‐SAL) and tributyltin propionate (TBT‐PROP) were purchased from Sigma (Schnelldorf, Germany), along with Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), RIPA lysis buffer, and other commonly used reagents. Antibiotics, including penicillin/streptomycin, gentamicin, and glutamine, were purchased from PAA Laboratories GmbH (Cölbe, Germany). Enzyme reagents were purchased from Roche Diagnostics (Mannheim, Germany). ZipTip C18 pipette tips were supplied by Merck Millipore (Billerica, MA, USA), and α‐cyano‐4‐hydroxycinnamic acid was purchased from LaserBio Labs (Sophia‐Antipolis Cedex, France). Cells and Treatment MDA‐MB‐231 cells (ATCC, VA, USA) were maintained in DMEM supplemented with FBS, L‐glutamine, penicillin, and streptomycin at 37°C in 5% CO2 and passaged weekly to 0.8–1.0 × 106 cells/mL. For experiments, cells were seeded in Ø40‐mm Petri dishes (TPP, Switzerland) at 1.2 × 106 cells/dish and allowed to attach for 24 h before treatment with 150‐nM TBT‐PROP or 200‐nM TBT‐SAL for 48 h. After incubation, cells were lysed in RIPA buffer, and lysates were stored at −70°C. Protein concentrations were measured by the Lowry assay, and 4 μg/μL of total protein was used per sample. Cell Viability Assay Cell survival in response to TBT‐PROP and TBT‐SAL was assessed using the MTT assay. Cells were seeded in Ø40‐mm dishes (TPP, Switzerland) at 1.2 × 106 cells per dish and allowed to attach for 24 h before exposure to varying concentrations of TBT derivatives for 48 h. Following treatment, 10 μL of MTT solution (Sigma‐Aldrich, MO, USA) was added, and cells were incubated in the dark at 37°C for 4 h. Formazan crystals were solubilized in 100‐μL DMSO, and absorbance was measured at 570 and 630 nm using a microplate reader (BioTek Instruments, VT, USA). IC50 values were calculated using the Quest Graph IC50 Calculator (AAT Bioquest). Data represent the mean of three independent experiments. 1D and 2D PAGE Purified samples were mixed with 300‐μL Laemmli buffer and denatured at 95°C for 10 min. Proteins were separated on 12% SDS‐PAGE at 140 V and stained with Coomassie Brilliant Blue G‐250. Two‐dimensional electrophoresis was performed using ReadyPrep 2D Starter Kit, ReadyStrip IPG strips (7 cm, pH 3–10), and 4%–20% Mini‐Protean TGX gels (Bio‐Rad, USA). Samples were dialyzed (Slide‐A‐Lyzer, Thermo Fisher), lyophilized, and rehydrated on IPG strips overnight, followed by isoelectric focusing at 50‐μA per strip. Strips were equilibrated, placed on TGX gels, and proteins were separated at 160 V. Gels were stained with Coomassie Brilliant Blue G‐250. In‐Gel Digestion Protein spots were excised, reduced with 50‐mM TCEP at 60°C for 1 h, and alkylated with 200‐mM MMTS for 10 min at room temperature. Digestion was performed overnight at 37°C with trypsin. Tryptic peptides were extracted with three washes of 5% TFA:acetonitrile (1:1 v/v) and purified using ZipTip C18 (Millipore). Aliquots (1 μL) were used for MALDI MS/MS analysis and protein identification prior to iTRAQ labeling. Isotopic Labelling iTRAQ iTRAQ labeling was carried out following the manufacturer's duplex kit protocol (AB Sciex). After tryptic digestion and C18 ZipTip desalting, peptides were labeled with reporter ions (m/z 114 for control; 116 and 117 for treated samples) for 90 min at room temperature. Equal amounts of labeled control and treated peptides were pooled (1:1), dried, desalted, and subjected to mass spectrometric analysis. Protein Relative Quantification Relative protein quantification was based on the peak intensities of iTRAQ reporter ions, with abundance ratios calculated from m/z 114/116 and 114/117 (control vs. treated). To ensure reliable quantification of iTRAQ reporter ions (m/z 114, 116, 117), spectra were acquired from multiple regions within each MALDI spot, and the resulting spectra were averaged. Mass Spectrometry and Database Searching For MALDI‐TOF/TOF MS, a solution of α‐cyano‐4‐hydroxycinnamic acid (10 mg/mL in ACN/0.1% TFA, in a 1:1 volume ratio) was used as the matrix. The sample was dissolved in 0.1% TFA, and 0.5 μL of the peptide solution was co‐crystallized with an equal volume of matrix solution directly on the MALDI target plate and allowed to air‐dry at room temperature. MALDI‐TOF/TOF measurements were performed using an AB Sciex 5800 MALDI‐TOF/TOF (Applied Biosystems, Foster City, CA, USA) operating in a result‐dependent acquisition mode. Both MS and MS/MS analyses were done in positive reflectron mode, with the micro‐channel plate detector set at 2.13 and 1.90 kV, respectively. The sample was excited using an Nd:YAG laser (355 nm) operated at a repetition rate of 400 Hz and acceleration voltage of 20 kV. For each spectrum, 3000–5000 laser shots were accumulated using a random acquisition pattern across the sample spot to minimize local heterogeneity. In MS/MS analyses, precursor ions were accelerated at 8 kV and then decelerated to 1 keV before entering the collision cell. Collision‐induced dissociation (CID) was performed using air as collision gas. Precursor ions were selected automatically using the AB Sciex 5800 MALDI‐TOF/TOF software according to intensity thresholds. Data acquisition and processing were carried out using 4000 Series Explorer software (Version 3.7). Signal‐to‐noise thresholds were set to 30 for MS and 15 for MS/MS analyses, and cluster area optimization was applied to improve peak selection. Peaks were analyzed over the m/z range from 68 to 50 units below the precursor ion, using mass tolerances of 0.6 Da for precursor ions and 0.3 Da for fragment ions. Proteins were considered successfully identified when the probability of a random match was lower than 0.05 and the identification was supported by at least two successfully fragmented peptides. Spectra were analyzed using Mascot searches against the Swiss‐Prot database (Version: 2024_01; 571 000 sequences; 198 754 198 residues) with the taxonomy Homo sapiens for real samples. Search settings included tryptic specificity with one missed cleavage, carbamidomethylation as a fixed modification, methionine oxidation as variable, and appropriate fixed/variable modifications for iTRAQ‐labeled peptides. Results MTT Assay Figure 1 shows the chemical structures of the analyzed compounds. Two commercially available compounds with active groups of triorganotin and propionic or salicylic acid were used to assess their effects on protein expression in MDA‐MB‐231 cells. The effects of TBT‐PROP and TBT‐SAL on breast cancer cell viability were assessed using the MTT assay. Both compounds exhibited cytotoxicity against the human MDA‐MB‐231 cell line. IC50 values, derived from the MTT results (Figure 2), were used to guide subsequent in vitro experiments. The structure of the investigated retinoid X receptor ligands. The course of MTT analysis reflecting the cytotoxicity range of tested compounds against human breast carcinoma cell line MDA‐MB‐231. IC50 were used for in vitro experiments. PDQuest Evaluation After individual treatment with TBT‐SAL and TBT‐PROP, changes in protein composition were assessed and the data obtained were compared with each other. In short, cell lysis was conducted following the instructions provided in Sigma's RIPA buffer manual. Prior to gel electrophoresis, samples were dialyzed using a Slide‐A‐Lyzer dialyzer with a cutoff of 2 kDa. These cassettes offer a rapid and efficient dialysis method due to their high surface‐to‐volume ratio. Following desalting, the samples were concentrated by lyophilization and subsequently resolved by one‐dimensional and two‐dimensional gel electrophoresis (Figure 3). Comparison of the obtained 1D/2D gel electropherograms of the control sample and individual samples treated with TBT‐PROP and TBT‐SAL. Selected Hsps and vimentin (as a marker) shown in the images were further cleaved by in‐gel, iTRAQ labeled, and identified by MALDI MS/MS. Protein maps were evaluated using PDQuest software (PDQuest Basic 2‐D Analysis software Version 8.0). Selected spots were examined in detail, and histograms generated by PDQuest software enabled accurate comparison of spot intensities across gels. Spots showing the greatest changes were excised and subjected to proteomic analysis, including tryptic digestion in gel, MALDI‐TOF MS/MS, and protein identification. Identified proteins were classified according to expression changes induced by each derivative, reflecting either upregulation or downregulation. Approximately 70 proteins were significantly altered (Table 1), with marked suppression observed in members of the Hsp family. TABLE 1Overview of selected proteins significantly affected by the investigated RXR ligands.SwissProt Accession (HUMAN)Mass (Da)Protein desctiptionProcess regulationBiological procesCellular processDevelopmental processMetabolic processApoptosisGene expressionCell migrationEpithelium developmentCell–cell adhesionCell differentiationFLNB280 157Filamin‐B••••••MYH9227 646Myosin‐9•••••••ENPL92 696Endoplasmin•••HS90A85 006Heat shock protein HSP 90‐alpha•••••••HS90B83 554Heat shock protein HSP 90‐beta•••••••CD4482 001CD44 antigen•••••••TRAP180 111Heat shock protein 75 kDa••••••••NUCL76 625Nucleolin•••••ODF2L74 651Protein BCAP••GRP7573 920Stress‐70 protein, mitochondrial•••••BIP72 402Endoplasmic reticulum chaperone BiP••••••••HSP7C70 263Heat shock 71 kDa••••••••EZRI69 484Ezrin••••••••RADI68 635Radixin••••••••H90B368 624Putative heat shock protein HSP 90‐beta‐3•••••CALX67 982Calnexin••••MOES67 892Moesin•••••••••TCPG62 507T‐complex protein 1 subunit gamma••KPYM59 911Pyruvate kinase PKM•••ATPA59 828ATP synthase subunit alpha, mitochondrial••••••NAMPT59 807Nicotinamide phosphoribosyltransferase••••K1C1059 020Keratin, type I cytoskeletal 10••••••ATPB56 525ATP synthase subunit beta, mitochondrial•••••VIME53 676Vimentin•••••••EF1A152 325Elongation factor 1‐alpha 1••••ASB1051 831Ankyrin repeat and SOCS box protein 10••TBA1A50 788Tubulin alpha‐1A chain•••TBB150 439Tubulin beta‐1 chain•EF1G50 429Elongation factor 1‐gamma•••PDIA650 220Protein disulfide‐isomerase A6••TBB4A50 010Tubulin beta‐4A chain•CALR48 142Calreticulin•••••••ENOA47 481Alpha‐enolase••••ENOB47 101Beta‐enolase••••HNRPF45 985Heterogeneous nuclear ribonucleoprotein F••••PGK144 985Phosphoglycerate kinase 1••••••ACTA44 831Actin, aortic smooth muscle••••••••ACTC42 334Actin, alpha cardiac muscle 1•••••••ACTB42 052Actin, cytoplasmic 1•••••••••HLAC41 136HLA class I histocompatibility antigen, C alpha chain•HLAA41 100HLA class I histocompatibility antigen, A alpha chain•••ROA138 837Heterogeneous nuclear ribonucleoprotein A1••••ANXA238 808Annexin A2•••••••ROA237 464Heterogeneous nuclear ribonucleoproteins A2/B1••••LDHA36 689L‐lactate dehydrogenase A••G3P36 201Glyceraldehyde‐3‐phosphate dehydrogenase••••ANXA535 937Annexin A5•••HNRPC33 707Heterogeneous nuclear ribonucleoproteins C1/C2•••••TPM132 746Tropomyosin alpha‐1 chain••••••NPM32 726Nucleophosmin••••SRS1031 339Serine/arginine‐rich splicing factor 10•••PGAM130 197Phosphoglycerate mutase 1•••1433B28 28214‐3‐3 protein beta/alpha•••••••PRDX328 017Thioredoxin‐dependent peroxide reductase•••••••1433Z27 74514‐3‐3 protein zeta/delta•••••••SRSF727 578Serine/arginine‐rich splicing factor 7••••SRSF925 640Serine/arginine‐rich splicing factor 9•••PRDX625 133Peroxiredoxin‐6•••SODM24 906Superoxide dismutase [Mn], mitochondrial••••••••GSTP123 569Glutathione S‐transferase P••••••RS922 635Small ribosomal subunit protein uS4••••PRDX122 324Peroxiredoxin‐1••••RS722 113Small ribosomal subunit protein eS7•••••SRSF319 546Serine/arginine‐rich splicing factor 3•••RS27A18 296Ubiquitin‐ribosomal protein eS31 fusion protein•PPIA18 229Peptidyl‐prolyl cis‐trans isomerase A••••••••NDKA17 309Nucleoside diphosphate kinase A••••••STMN117 303Stathmin•••••CALM116 827Calmodulin‐1••••PROF115 216Profilin‐1••••••• Note: The pink‐highlighted cells indicate the members of Hsp family that are the focus of this study. Overview of selected proteins significantly affected by the investigated RXR ligands. Note: The pink‐highlighted cells indicate the members of Hsp family that are the focus of this study. iTRAQ Quantification of Hsps To further verify the results of 2D‐PAGE (Figure 3), iTRAQ labeling was used for relative quantification of Hsps. iTRAQ enables simultaneous labeling and quantification of all peptides in a sample, thereby improving the identification and measurement of specific proteins in complex mixtures. Following in‐gel digestion, individual peptide samples were labeled with isobaric iTRAQ reagents corresponding to reporter ions of 114 m/z, as well as 116 or 117 m/z. In this study, the 114 label was assigned to the control group, whereas the 116 and 117 labels were used for samples treated with the individual derivatives, allowing direct comparison between the different treatments. The iTRAQ‐labeled samples, encompassing both control and individually treated groups, were pooled in equimolar (1:1) ratios and directly analyzed by MALDI‐TOF mass spectrometry. In the MS/MS spectra, identical peptides modified with iTRAQ reagents from different experimental conditions generated distinct reporter ion signal intensity ratios (114/116 and 114/117 m/z), which quantitatively reflected the relative protein abundance across the analyzed samples. The findings from the analysis are summarized in Figure 4. For a clearer explanation, the peak area ratio values were converted to percentages, while the amount of protein in the control sample was set to 100%. The protein amount in the corresponding treated sample was then expressed as a percentage of the original amount in the control sample. Figure 4 also shows the results of reduced expression of vimentin as a marker after treatment with both TBT derivatives. Graphical representation of the decreasing trend of Hsps after treatment with each derivative and iTRAQ labeling. The graph includes the protein vimentin, which represents a marker. Data are presented as mean ± SD (n = 3). Statistical significance was evaluated using a two‐tailed Student's t test (*p < 0.05, **p < 0.01). The employed approach additionally verified that Hsp expression levels were diminished subsequent to treatment with both ligand classes. All experiments were performed in triplicate, and the resulting data were averaged. Figure 5 of the fragmentation spectra of the selected peptides corresponding to the given proteins shows the principle of iTRAQ quantification. The spectra magnified over the range of isobaric markers m/z 114 for control, 116 for TBT‐PROP, and 117 for TBT‐SAL show the ratio of control to treated samples. The peak area ratios of selected iTRAQ‐modified peptides for each protein reflect the relative abundance of these proteins in each sample (control versus specific treatment). Table S1a,b summarizes the intensities and areas for m/z 114, 116, and 117, as well as their ratios, which were used to determine the relative abundance of the selected proteins. Quantification of individual protein based on MALDI MS/MS analysis; the overview of spectra zoomed in the range of isobaric tages of m/z 114–117 showing the ratio of control and treated samples. The peak area ratios of chosen iTRAQ modified peptides of individual proteins correspond to the relative proportion of these proteins in the individual samples (control versus particular treatment). All measurements were performed in triplicate and the average value was determined. The results show that the proteins we investigated, including Hsp90‐alpha, beta, Hsp70, Hsp71, Hsp75, and BIP, were significantly reduced by both derivatives, TBT‐PROP and TBT‐SAL. We found a significant decrease in the level of Hsp90‐alpha, while a minor downward trend in the expression of this protein was observed in the case of Hsp90‐beta. The decrease in Hsp90‐alpha levels confirmed at the protein level is particularly pronounced when using the TBT‐PROP derivative. Within the spectrum of downregulated proteins, we also focused on Hsp70, for which both TBT‐PROP and TBT‐SAL caused a significant reduction in its expression. The reduction in protein in this case was approximately 50% of the original amount. While HSP70 was strongly affected by both RXR ligands, on the other hand, HSP75 was mainly affected by TBT‐SAL, but it should be emphasized that the decrease was not as pronounced as expected. Table 2 summarizes information on these Hsps that differ after triorganotin derivatives treatment compared with untreated cells, along with their biological functions and associations with breast cancer. TABLE 2Summary of the extent of downregulation of Hsps and their importance in breast cancer‐related processes.SwissProt AccessionsProtein descriptionApoptosis resistanceMetastasisEMTCancer cell stemnesAngiogenesisTumor invasionCell proliferationTumor immunityRate of downregulation (%)DerivatePropionateSalicylateENPL_HUMANEndoplasmin•••42.250.7HS90A_HUMANHeat shock protein HSP 90‐alpha•••53.534.2HS90B_HUMANHeat shock protein HSP 90‐beta•••24.816.0TRAP1_HUMANHeat shock protein 75 kDa•••13.128.5GRP75_HUMANHeat shock 70 kDa••••57.449.5BIP_HUMANEndoplasmic reticulum chaperone BiP•46.249.0HSP7C_HUMANHeat shock cognate 71 kDa••••36.325.4 Summary of the extent of downregulation of Hsps and their importance in breast cancer‐related processes. Figure 6A presents a representative MALDI‐TOF MS spectrum of a mixed control and treated iTRAQ‐labeled tryptic digest of Hsp90‐beta, showing the characteristic 144 m/z mass shift following labeling. The corresponding MS/MS spectrum of the peptide GVVDSEDLPLNISR at 1657.59 m/z is shown in Figure 6B, with an expanded view of the reporter ion ratios at 114/116 (propionate treatment) and 114/117 m/z (salicylate treatment), enabling relative quantification of Hsp90‐beta between control and treated samples. (A) Example of MALDI‐TOF MS analysis corresponding to heat shock protein Hsp90‐beta; upper spectrum represents sample before iTRAQ labeling; the lower spectrum is obtained after iTRAQ labeling. The mass shift of iTRAQ labeling of Tyr and Cys (144 Da) is marked between both spectra. The amino acid sequence of the identified Hsp90‐beta with the obtained peptides highlighted in bold is shown in the right part of the figure. (B) Example of the fragmentation MS/MS spectrum of a peptide tagged with iTRAQ at 1657.69 m/z (GVVDSEDLPNISR) corresponding to the Hsp90‐beta. The magnified peak ratio area at 114/116 and 114/117 m/z and their relative intensities reflect the relative quantification of the protein. Alignment of the Hsp sequences with the identified iTRAQ‐labeled peptides is also depicted (Figure 6B, top right). Quantitative analysis of the control and treated sample ratios indicates that Hsp90‐beta levels decreased by 16% following TBT‐SAL treatment and by 25% following TBT‐PROP treatment. Discussion As there are still many toxic side effects on surrounding cells and the body as a whole with the use of current chemotherapeutics, the development of new compounds is critically needed. Breast cancer is a worldwide problem and, particularly in the ‘triple‐negative’ form, it is essential, given its aggressive nature, to develop chemotherapeutic agents which, in practice, can improve the prognosis of treatment. Therefore, we studied the antitumor effects of TBT‐PROP and TBT‐SAL, novel synthetic nuclear RXR ligands. RXR ligands hold potential for treating a variety of conditions, including diabetes, obesity, cancer, and Alzheimer's disease, making them promising candidates for therapeutic interventions in these areas [20]. Various treatments with natural retinoic acid (RA) ligands were applied to human triple‐negative breast cancer MDA‐MB‐231 cells. The cells were treated in the presence or absence of the natural retinoid receptor ligand ATRA. ATRA treatment resulted in a significant reduction in the levels of vimentin and CD44 in both cytoplasmic and membrane protein fractions. This effect was particularly pronounced for CD44, whose protein level in the cytoplasmic fraction was almost completely abolished [21]. In 2017, ATRA, 9cRA, and their combination were investigated [22]. The results supported the hypothesis that RA derivatives are associated with a reduction in vimentin levels, along with other key proteins. Nevertheless, the decrease in vimentin observed after ATRA and 9cRA treatment was less pronounced than originally anticipated. For this reason, recent studies have increasingly directed attention toward commercially available synthetic organotin derivatives, such as TBT‐Cl and TPT‐Cl, which have been reported to act as ligands of the nuclear RXR [10, 23]. Extensive research has shown that Hsps are highly expressed in various types of human cancers and are closely related to tumorigenesis [24]. Available evidence further indicates that Hsps support cancer cell proliferation by maintaining the proper composition and functionality of proteins involved in cell cycle progression. In addition, Hsps have been implicated in processes that contribute to the enhanced metastatic potential of cancer cells [25]. Hsp70 and Hsp90 contribute to enhancing the resistance of cancer cells, including MDA‐MB‐231 cells, to chemotherapy and radiotherapy by helping to repair damaged proteins and DNA after exposure to these therapeutic agents, resulting in the survival of cancer cells that would otherwise be destroyed [26]. In addition, Hsps can stabilize proteins involved in drug resistance mechanisms, such as drug transporters, contributing to reduced treatment efficacy. Therefore, a highly invasive, poorly differentiated triple‐negative breast cancer cell line without estrogen and progesterone receptors and without HER2 expression was selected for this study, reflecting its aggressive phenotype and limited availability of therapeutic options [27]. Elucidating the molecular mechanisms of triple‐negative breast cancer is essential for the development of effective therapeutic strategies. Additionally, it is crucial to create treatment options that minimize side effects [28]. Triphenyltin and tributyltin derivatives may serve as a promising group of treatments aimed at reducing Hsp levels, which play a key role in regulating actin dynamics and cell motility. Given their critical role in cancer cell survival, proliferation, and metastasis, Hsps are considered promising targets for cancer therapy. In MDA‐MB‐231 cells, inhibition of Hsps has been demonstrated to impair cancer cell growth, induce apoptosis, and increase cell sensitivity to chemotherapeutic drugs. It is interesting to note that tumor cells rely more on Hsp chaperones for their proliferation compared to normal cells, which has prompted the development of various Hsp90 inhibitors. Several Hsp90 inhibitors, including 17‐AAG, an active site ATP‐binding site analog, are currently in clinical trials and show promise in the treatment of breast cancer and other malignancies [29]. Inhibition of Hsp70 in combination with Hsp90 inhibitors is also considered an interesting strategy. Treatment with Hsp90 inhibitors has been reported to induce Hsp70 expression, a phenomenon observed both in vitro in leukemia cells and in vivo in tumors of treated patients [30]. RXR ligands could modulate the heat shock response, potentially by suppressing the expression of key stress response proteins. Given the frequent resistance to treatment observed in cancer cells such as MDA‐MB‐231, which is associated with elevated levels of Hsp, downregulation of Hsp expression may offer potential therapeutic benefits. By reducing the protective functions of Hsp, this strategy could make cancer cells more vulnerable to stress induced by chemotherapy or other therapeutic interventions [25]. Conclusions To conclude, in MDA‐MB‐231 cells, Hsps are crucial in promoting cell survival, tumor progression, metastasis, and treatment resistance. Targeting these proteins may thus represent a promising strategy to sensitize cancer cells to different therapies. As understanding of the specific roles of Hsps in breast cancer improves, Hsp inhibitors could become an important adjunct to therapies used to treat aggressive breast cancers. The data from this study relate to an important and new area of cancer research and offer a further opportunity for more intensive study of triorganotins in order to exploit the direct activation of RXR by triorganotins. Therefore, further investigation of triorganotins as potential therapeutic agents is warranted. Author Contributions Janette Bobalova and Julius Brtko conceived, supervised the study, and designed experiments; Dana Strouhalova and Dana Macejova performed experiments and provided methodology. The manuscript was written by Janette Bobalova, with all authors contributing to the writing and critical revision of the final manuscript. Funding This work was supported by institutional support (RVO:68081715), Agentúra na Podporu Výskumu a Vývoja (APVV‐20‐0314 and APVV‐19‐0093), and Vedecká Grantová Agentúra MŠVVaM SR a SAV (2/0116/21). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1a: Summary of the intensity values and area ratios for m/z 114, 116, and 117 used to determine the relative abundance of proteins differentially expressed after TBT‐PROP and TBT‐SAL treatments. Table S1b: Identification of differentially expressed proteins by MALDI MS/MS.